MediPoint: Total Ankle Replacement - US Analysis And Market Forecasts
NEW YORK, April 11, 2013 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
MediPoint: Total Ankle Replacement - US Analysis and Market Forecasts http://www.reportlinker.com/p01158477/MediPoint-Total-Ankle-Replacement---US-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic
MediPoint: Total Ankle Replacement - US Analysis and Market Forecasts
SummaryAnkle arthritis is a severe and debilitating problem with notable increasing prevalence in both the developed and developing world. In a society constantly seeking out a modern lifestyle, sports-related injuries, trauma, aging, and obesity are contributing to an increased incidence of ankle arthritis. Total ankle replacement (TAR) enables implantation of prosthesis within the diseased native ankle joint to help patients maintain their ankles' range of motion. Promising results of newer generation prostheses revived interest in TAR and fueled further innovations in the prosthetic design. After decades of trial and error, TAR is now becoming a promising option for late-stage ankle arthritis patients as an alternative to ankle fusion, which has historically been presumed to be the gold-standard procedure. This report focuses on the TAR markets in the US. This report identifies unmet needs in the market, surgeon attitudes towards current TAR prostheses, and the future of TAR in the face of rapid technological advancement.Early experience with TAR in the US was met with unacceptable failure and complication rates in the 1980s, such that the procedure was largely abandoned. In the past decade, newer generations of TAR prostheses with a more anatomical replication of the ankle joint demonstrated some encouraging early and medium-term clinical results. Meanwhile, long-term results following successful early ankle fusion have brought to light somewhat disappointing long-term satisfaction rates. TAR is becoming an increasingly popular alternative to ankle fusion lately, as professional and commercial interest intensifies and long-term effectiveness becomes available.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts